Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients younger than 24 weeks.~* Presenting a hemangioma with the following characteristics:~* Subcutaneous and/or cutaneous~* Minimum diameter of 1.5 cm on face, 3 cm outside face and 1.5 cm if it is ulcerated.~* Consent of both parents (or the person having parental authority in families)~Exclusion Criteria:~* Infant presenting contraindications for the administration of propranolol or atenolol.~* Hemangioma has been previous treated with corticosteroids, laser, cryotherapy, or only other treatments.~* Patients with an inability to participate or to follow the study treatment and assessment plan.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Weeks
- Healthy Volunteers: t

Study Arms:
- Propranolol (Type: ACTIVE_COMPARATOR): Propranolol
- Atenolol (Type: ACTIVE_COMPARATOR): Atenolol

Based on this trial design, predict the completion outcome and termination type (if applicable).